Clinical Trial Update: An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Exploratory Phase 2 trial examining surufatinib in combination with chidamide and fulvestrant for HR-positive unresectable metastatic breast cancer; status not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Chidamide (chidamide)
• Fulvestrant (fulvestrant)
• Surufatinib (Surufatinib)

Snippet

Sponsor: The First Affiliated Hospital of Zhengzhou University | Conditions: Breast Cancer, Breast Cancer Female | Phase 2 | Status: UNKNOWN